Citations

Clear

2960 citation(s) found for "Kim, P".

Single Cell Untargeted Lipidomics Using Liquid Chromatography Ion Mobility-Mass Spectrometry
Kim, Jin Yong , Ding, Husheng, Forsberg, Erica M. , Meyer, S. , Barsch, Aiko , Pandey, Akhilesh , Byeon, Seul Kee , Kim, Jinyong , Meyer, Sven W , Pandey, Akhilesh , Byeon, Seul Kee , Mun, Dong‐Gi

Mayo Clinic

Journal of Proteome Research | February 14, 2025 | Volume: 24 | Issue: 4 | Pages: 1579-1585

10.1021/acs.jproteome.4c00658 | PMID 39950635 Get It

Catheter Injectable Multifunctional Biomaterial for the Treatment of Infected Enterocutaneous Fistulas
Albadawi, Hassan , Keum, Hyeongseop , Mayer, Joseph L. , Öklü, Rahmi , Kim, Jinjoo , Zhang, Zefu , Graf, Erin H. , Oklu, Rahmi

Mayo Clinic

Advanced Science | February 14, 2025 | Volume: 12 | Issue: 20 | Pages: No page available

10.1002/advs.202414642 | PMID 39950851 Get It

Abstract Enterocutaneous fistulas (ECF) are challenging to treat contributing to high morbidity and high mortality rates, significantly impacting the quality of life of the patients. Its susceptibility to antibiotic‐resistant infections often leads to chronic inflammation, complicating treatment with conventional methods. Here, 18NC75‐10P‐1IL is reported, which is a multi‐functional shear‐thinning hydrogel comprised of gelatin and nanosilicates for injectability, an ionic liquid for bactericidal effects, and platelet rich fibrin fraction for pro‐healing properties; this biomaterial is engineered for the treatment of ECFs. Through rigorous testing, the mechanical properties of 18NC75‐10P‐1IL were tailored for catheter injection to achieve durable occlusion of fistulous tracts under external pressures simulating clinical scenarios. 18NC75‐10P‐1IL demonstrated pro‐healing effects and anti‐microbial activity against highly resistant patient‐derived bacteria known to be associated with ECF. Subcutaneous implantation and anorectal fistula models confirmed its biocompatibility, pro‐healing, anti‐inflammatory, and anti‐microbial properties compared to control materials, suggesting promising potential for clinical translation in the treatment of human ECFs.
Comparative outcomes of arteriovenous malformations treatment in eloquent versus non-eloquent brain: A multicenter study with propensity-score weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Aslan, Assala , Tjoumakaris, Stavropoula I, Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Erginoğlu, Ufuk , Sen, Rajeev , Griessenaur, Christoph, Burkhardt, Jan‐Karl , Starke, Robert M., Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Abla, Adib A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew, Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan , Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael T. , Guthikonda, Bharat , Salim, Hamza , Dmytriw, Adam A , Levitt, Michael R , Chen, Peng R , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Altschul, David J , Ogilvy, Christopher S , Alwakaa, Omar , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Mantziaris, Georgios , Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Koch, Matthew J. , Blackburn, Spiros , Kim, Louis J. , Choudhri, Omar , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

International Journal of Stroke | February 14, 2025 | Volume: 20 | Issue: 7 | Pages: 852-863

10.1177/17474930251323503 | PMID 39948730 Get It

Background: Arteriovenous malformations (AVMs) are complex vascular anomalies with a high risk of hemorrhage and neurological deficits, especially when located in eloquent brain regions. The eloquence of an AVM location is a critical factor in the treatment planning, influencing both the risk of complications and long-term functional outcomes. This study aims to compare outcomes between eloquent and non-eloquent AVMs. Methods: This multicenter, retrospective study utilized data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium. Patients with eloquent and non-eloquent AVMs were compared on baseline characteristics, angiographic outcomes, and functional outcomes using the modified Rankin Scale (mRS). Propensity score weighting (IPTW) was applied to adjust for confounding variables. Results: The study included 1013 patients, with 498 (49.2%) AVMs located in eloquent regions and 515 (50.8%) in non-eloquent regions. In unadjusted analysis, eloquent AVMs had lower complete obliteration rates (67.6% vs 79.5%, OR: 0.53, 95% CI: 0.39–0.72, p < 0.001) and higher complication rates (24.5% vs 19.0%, OR: 1.38, 95% CI: 1.02–1.86, p = 0.03) compared to non-eloquent AVMs. After IPTW adjustment, eloquent AVMs continued to show significantly higher odds of overall complications (OR: 1.68, 95% CI: 1.12–2.52, p = 0.01) and symptomatic complications (OR: 1.77, 95% CI: 1.12–2.80, p = 0.01). Secondary analysis within the eloquent group indicated that embolization was linked to an elevated risk of complications. Surgery and radiosurgery showed comparable functional outcomes at last follow-up and complications rates with higher complete obliteration rates in surgery. Conclusion: AVMs in eloquent brain areas present higher risks of complications and lower obliteration rates, emphasizing the need for cautious, individualized treatment planning. Within the eloquent group, embolization increased the risk of complications, while surgery and radiosurgery showed comparable functional outcomes at last follow-up and complication rates with higher complete obliteration rates in surgery. These findings highlight the importance of location in AVM management and support further research focusing on comparing treatment strategies for AVMs in eloquent brain areas.
Illuminating the Challenges and Diagnostic Utility of Plasma Microbial Cell-Free DNA Sequencing in Suspected Infective Endocarditis: A Retrospective Observational Cohort Study
Kim, Myeongji , Garcia, Sofia Molina , Razi, Samrah, Ranganath, Nischal , Saleh, Omar Abu , Molina Garcia, Sofia , Ranganath, Nischal , Mahmood, Maryam , Abu Saleh, Omar , Damronglerd, Pansachee , Yetmar, Zachary A. , Mahmood, Maryam

Mayo Clinic

Open Forum Infectious Diseases | February 13, 2025 | Volume: 12 | Issue: 3 | Pages: No page available

10.1093/ofid/ofaf099 | PMID 40046887 Get It

Abstract Background Infective endocarditis (IE) is a life-threatening infection often challenging to diagnose, particularly in culture-negative cases. Plasma microbial cell-free DNA (mcfDNA) sequencing has shown potential for detecting pathogens in IE. However, its clinical utility, diagnostic impact, and limitations remain debated. This study evaluates its use in diagnosing and managing IE in a tertiary care setting. Methods This single-center retrospective cohort study included adult patients (≥18 years) who underwent mcfDNA sequencing via the Karius test for suspected IE at Mayo Clinic Rochester between December 2019 and February 2024. Diagnostic classification followed the 2023 Duke–International Society of Cardiovascular Infectious Diseases criteria. Data on demographics, clinical features, routine microbiologic workup, and mcfDNA sequencing results were collected. Statistical analysis was conducted to evaluate diagnostic utility and treatment impact. Results Among 141 patients, 66 had a diagnosis of IE, with mcfDNA sequencing identifying pathogens in 60.6% of them, compared with 39.4% with routine workup. mcfDNA sequencing was the sole microbiologic test with positive results in 33.3% of patients, leading to antimicrobial adjustments in 50.0% of that group. Clinically insignificant mcfDNA sequence detection occurred in 28.6% of patients without a diagnosis of IE. Conclusions mcfDNA sequencing is a valuable adjunctive tool for diagnosing culture-negative IE and guiding antimicrobial therapy when clinical suspicion is high. However, its utility depends on appropriate clinical context, highlighting the need for careful test interpretation and further prospective studies to assess patient-centered outcomes and cost-effectiveness.
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
Danpanichkul, Pojsakorn , Chen, Vincent , Saokhieo, Preenapun , Dejvajara, Disatorn , Sukphutanan, Banthoon , Lopimpisuth, Chawin , Pang, Yanfang , Fallon, Michael B. , Kim, Donghee , Yang, Ju Dong , Aqel, Bashar , Chen, V L , Saokhieo, Preenapun , Huang, Daniel Q , Kim, Donghee , Singal, Amit , Yang, Ju Dong , Aqel, Bashar A. , Terrault, Norah , Wijarnpreecha, Karn , Danpanichkul, Pojsakorn , Duangsonk, Kwanjit , Aboona, Majd B. , Ibrahim, Andrew , Huang, Daniel Q. , Singal, Amit G. , Terrault, Norah A. , Wijarnpreecha, Karn

Mayo Clinic

Hepatology | February 12, 2025 | Volume: 82 | Issue: 5 | Pages: 1274-1286

10.1097/hep.0000000000001260 | PMID 39937958 Get It

Backgrounds and Aims: HBV-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver cancer (PLC) persist. We evaluate global trends in the prevalence, incidence, and death of HBV-related liver disease. Approach and Results: Data from the Global Burden of Disease Study 2021 evaluated acute HBV infection, HBV-related cirrhosis, and HBV-related liver cancer prevalence, incidence, and death. In 2021, there were 7.30 million cases of acute HBV, 283.64 million cases of HBV-related cirrhosis, and 288,110 cases of HBV-related PLC. HBV-related PLC accounted for 39% of the global incidence of PLC; Western Pacific had the highest rates for HBV-related PLC, with an incidence of 5.24 and a death rate of 4.38 per 100,000 population. Between 2000 and 2021, age-standardized incidence, prevalence, and death rates from HBV-related liver disease decreased; however, the incidence of HBV-related PLC rose in 65 countries from 2000 to 2021. In parallel, age-standardized prevalent rates from HBV-related PLC increased in Europe (annual percent change: 0.77%, 95% CI: 0.72%–0.81%) and the Americas (annual percent change: 1.05%, 95% CI: 1.00%–1.10%). Conclusions: From 2000 to 2021, decreases in HBV-related liver disease incidence and prevalence were observed; however, more than one-third of countries showed an increase in the incidence of HBV-related PLC. These findings highlight the need for strengthened HBV treatment efforts to reduce the risk of liver cancer.
Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus
Laun, Sarah , Kann, Lisa , Braun, Jerome J., Pierre, Francia , Kim, Suji , Gilbert, Stacey, Lunz, Daniel, Kalra, Andrew , Cheng, Yulan , Leggett, Cadman L. , Omstead, Ashten N., Korman, Louis Y. , Jobe, Blair A. , Perpetua, Lorrie A., Greenwald, Bruce D. , Maddala, Tara, Meltzer, Stephen J. , Leggett, Cadman L , Zaidi, Ali Hussainy , Greenwald, Bruce D , Meltzer, Stephen J , Braun, Jerome, Ma, Ke

Mayo Clinic

American Journal of Gastroenterology | February 11, 2025 | Volume: 120 | Issue: 6 | Pages: 1285-1295

10.14309/ajg.0000000000003367 | PMID 39933887 Get It

INTRODUCTION: Barrett esophagus (BE) is the strongest known risk factor for developing esophageal adenocarcinoma (EAC), the second-most lethal cancer in the United States. Esopredict is a novel validated methylation-based biomarker assay that provides precise quantification of neoplastic progression risk in BE patients. Inherit challenges, including tissue heterogeneity, sampling error, interobserver variability, and inconsistent adherence to surveillance biopsy guidelines, may affect the predictive value results of Esopredict obtained at different anatomic locations or different sampling time points. METHODS: To investigate the spatiotemporal performance of Esopredict across multiple spatiotemporal sampling points, we profiled 220 biopsies obtained from 58 BE patients, including 11 patients with overlapping spatial and temporal biopsies. We focused on spatial profiling (i.e., multiple biopsies obtained at several anatomic locations during a single endoscopy) and temporal profiling (i.e., biopsies obtained from multiple endoscopies performed at different time points). Each patient had an initial histologic diagnosis of nondysplastic Barrett esophagus, indefinite for dysplasia, or low-grade dysplasia. Final follow-up (endpoint) biopsies showed either high-grade dysplasia or EAC (progressors), or nondysplastic Barrett esophagus, indefinite for dysplasia, or low-grade dysplasia (nonprogressors). Biopsies were analyzed with Esopredict to compute a progression risk score, which quantified the likelihood of future progression to high-grade dysplasia or EAC within 5 years. RESULTS: In 52 spatially profiled patients, Esopredict demonstrated a sensitivity of 81% (17/21 progressor patients), based on the highest-scoring biopsy from each patient; sensitivity increased to 100% (12/12) when end point biopsies occurred within 5 years of the index (initial) biopsy. In 28 temporally profiled patients, sensitivity was 100% (8/8 patients), based on the biopsy performed at the time point closest to the end point biopsy. DISCUSSION: Esopredict showed high predictive performance in multiple spatiotemporal samples in BE patients. These data further support the use of Esopredict as a robust test to distinguish high-risk BE patients, who may benefit from endoscopic eradication therapy or increased surveillance frequency, from low-risk patients, who may be candidates for less frequent surveillance and noninterventional observation.
Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD
Kwon, Young Nam , Tisavipat, Nanthaya , Guo, Yong , Han, Ji Yeon , Kim, Jun‐Soon , Choi, Kyomin , Oh, Seong‐il , Choi, Seok‐Jin , Sohn, Eun Hee , Kim, Seung Woo , Shin, Ha Young , Kim, Byoung Joon , Park, Kyung Seok , Sung, Jung‐Joon , Kim, Se Hoon , Ζεκερίδου, Αναστασία , Lucchinetti, Claudia F. , Pittock, Sean J. , Chen, John J. , Kim, Sung‐Min , Pittock, S J , Syc-Mazurek, Stephanie B , Han, Ji Yeon , Kim, Jun-Soon , Choi, Kyomin , Oh, Seong-Il , Choi, Seok-Jin , Sohn, Eunhee , Oh, Jeeyoung , Kim, Seung Woo , Shin, Ha Young , Lim, Byung Chan , Sung, Jung-Joon , Park, Sung-Hye , Zekeridou, Anastasia , Lucchinetti, Claudia F , Chen, John J , Guo, Yong , Tisavipat, Nanthaya , Syc‐Mazurek, Stephanie B. , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 11, 2025 | Volume: 12 | Issue: 4 | Pages: 861-870

10.1002/acn3.52301 | PMID 39932929 Get It

AbstractCases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age‐ and country‐adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.
The influence of prestroke disability on outcome in patients with a low Alberta Stroke Program Early CT Score who underwent endovascular thrombectomy
Uchida, Kazutaka , Maier, Ilko , Jabbour, Pascal , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Mascitelli, Justin, Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Crosa, Roberto , Wolfe, Stacey Quintero , Fragata, Isabel , Matsukawa, Hidetoshi , Elawady, Sameh Samir , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Levitt, Michael R. , Moss, Mark, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Journal of Neurosurgery | February 7, 2025 | Volume: 143 | Issue: 1 | Pages: 266-273

10.3171/2024.10.jns24888 | PMID 39919282 Get It

OBJECTIVE The definitive influence of prestroke disability on outcomes in patients with a low Alberta Stroke Program Early CT Score (ASPECTS) treated with endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) due to large-vessel occlusion (LVO) remains unknown. This study aimed to investigate the impact of prestroke disability on outcomes in this specific population. METHODS Data from 32 international centers for AIS-LVO patients with a low ASPECTS who underwent EVT between January 2013 and December 2022 were analyzed retrospectively. Low ASPECTS and prestroke disability were defined as ASPECTS values of 2–5 and prestroke modified Rankin Scale (mRS) score ≥ 2. The primary outcome was a return to the prestroke mRS score at 90 days. Secondary outcomes were independent ambulation (mRS scores of 0–3) or a return to the prestroke mRS score at 90 days, good functional outcome (mRS scores of 0–2) or a return to the prestroke mRS score at 90 days, successful recanalization, and 90-day mortality. Safety outcomes were any intracranial hemorrhage or symptomatic intracranial hemorrhage. A symptomatic intracranial hemorrhage was defined as an intracranial hemorrhage with an associated worsening of ≥ 4 points in the National Institutes of Health Stroke Scale score. Outcomes were compared between patients with and without prestroke disability. RESULTS Of 293 patients, 50 (17.1%) had a prestroke disability. Of 50 patients, 20 (40.0%), 24 (48.0%), and 6 (12.0%) had prestroke mRS scores of 2, 3, and 4, respectively. The primary outcome showed no significant difference between the two groups. Compared with patients without prestroke disability, those with prestroke disability had a significantly smaller proportion of independent ambulation or return to prestroke mRS score (adjusted OR 0.13, 95% CI 0.03–0.53) and good functional outcome or return to prestroke mRS score (adjusted OR 0.21, 95% CI 0.05–0.91). Other secondary and safety outcomes showed no significant difference between the two groups. CONCLUSIONS The present study indicated that prestroke disability was not associated with a return to the prestroke mRS score at 90 days or intracranial hemorrhage. Physicians should not routinely exclude AIS-LVO patients with a low ASPECTS who have prestroke disability from EVT based on prestroke disability alone.
Decoding Mucosal Melanomas: Genetic Profiling for Advanced Therapeutic Strategies
Alshaka, Saif, Hsia, Beau, Bitar, Gabriel , Crawford, John, Levy, Danielle, Valecia, Bastien, Hsia, Beau , Sato, Mariko , Levy, Michael L. , Kim, Jeeho D. , Faraji, Farhoud , Patel, Vijay A. , Polster, Sean P.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803335 Get It

Characterizing Common Mutations in Nasopharyngeal Carcinomas: Pathways to Targeted Therapy Development
Hsia, Beau, Bitar, Gabriel , Alshaka, Saif, Crawford, John, Levy, Danielle, Hsia, Beau , Sato, Mariko , Crawford, John, Levy, Michael L. , Valencia, Bastien A. , Kim, Jeeho D. , Faraji, Farhoud , Patel, Vijay A. , Polster, Sean P.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803334 Get It